Sutro Biopharma
Update in progressSTRO (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Sutro Biopharma, Inc. is an oncology company developing site-specific antibody drug conjugates using its XpressCF cell-free platform. Its lead STRO-004 targets tissue factor in TF-expressing solid tumors. The firm pursues VAX-24 and VAX-31 pneumococcal vaccines and STRO-003, an ROR1-directed ADC for solid and hematologic cancers. It collaborates with Vaxcyte, Tasly, Ipsen and Astellas. Based in South San Francisco, founded 2003.
Company score
- Sentiment
- -0.30
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- -0.06
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.23
- Governance
- -0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.20
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationUnited States
- CEOMs. Jane Chung R.Ph.
- Founded2003
- Employees128
- Websitewww.sutrobio.com
Identifiers
- ISINUS8693671021
- FIGIBBG000R4V3P3
- LEI5493005U6P15VD25P851
- CUSIP869367102
- CIK0001382101